Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer | Zendy

Josephine F. Trott | Zendy; Omran Abu Aboud | Zendy; Bridget McLaughlin | Zendy; Katie L. Anderson | Zendy; Jaime F. Modiano | Zendy; Kyoungmi Kim | Zendy; KuangYu Jen | Zendy; William Senapedis | Zendy; Hua Chang | Zendy; Yosef Landesman | Zendy; Erkan Baloglu | Zendy; Роберто Пили | Zendy; Robert H. Weiss | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer

Author(s) -

Josephine F. Trott,

Omran Abu Aboud,

Bridget McLaughlin,

Katie L. Anderson,

Jaime F. Modiano,

Kyoungmi Kim,

KuangYu Jen,

William Senapedis,

Hua Chang,

Yosef Landesman,

Erkan Baloglu,

Роберто Пили,

Robert H. Weiss

Publication year - 2020

Publication title -

kidney360

Language(s) - English

Resource type - Journals

ISSN - 2641-7650

DOI - 10.34067/kid.0000282019

Subject(s) - kidney cancer , medicine , renal cell carcinoma , cancer , antibody , cancer research , kidney , malignancy , immune system , cancer cell , immunology

Kidney cancer (or renal cell carcinoma, RCC) is the sixth most common malignancy in the United States and is increasing in incidence. Despite new therapies, including targeted therapies and immunotherapies, most RCCs are resistant to treatment. Thus, several laboratories have been evaluating new approaches to therapy, both with single agents as well as combinations. Although we have previously shown efficacy of the dual PAK4/nicotinamide phosphoribosyltransferase (NAMPT) inhibitor KPT-9274, and the immune checkpoint inhibitors (CPI) have shown utility in the clinic, there has been no evaluation of this combination either clinically or in an immunocompetent animal model of kidney cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research